DE602005026143D1 - Erkennung eines erhöhten spiegels von her-2/neu-proteinen in zirkulierenden krebszellen und dessen behandlung - Google Patents

Erkennung eines erhöhten spiegels von her-2/neu-proteinen in zirkulierenden krebszellen und dessen behandlung

Info

Publication number
DE602005026143D1
DE602005026143D1 DE602005026143T DE602005026143T DE602005026143D1 DE 602005026143 D1 DE602005026143 D1 DE 602005026143D1 DE 602005026143 T DE602005026143 T DE 602005026143T DE 602005026143 T DE602005026143 T DE 602005026143T DE 602005026143 D1 DE602005026143 D1 DE 602005026143D1
Authority
DE
Germany
Prior art keywords
cancer cells
neu
treatment
recognition
circulating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005026143T
Other languages
English (en)
Inventor
Robert M Lorence
Ming Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Biologics Corp
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Publication of DE602005026143D1 publication Critical patent/DE602005026143D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
DE602005026143T 2004-10-06 2005-10-06 Erkennung eines erhöhten spiegels von her-2/neu-proteinen in zirkulierenden krebszellen und dessen behandlung Active DE602005026143D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61633204P 2004-10-06 2004-10-06
PCT/US2005/035894 WO2006041959A2 (en) 2004-10-06 2005-10-06 Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment

Publications (1)

Publication Number Publication Date
DE602005026143D1 true DE602005026143D1 (de) 2011-03-10

Family

ID=36148887

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005026143T Active DE602005026143D1 (de) 2004-10-06 2005-10-06 Erkennung eines erhöhten spiegels von her-2/neu-proteinen in zirkulierenden krebszellen und dessen behandlung

Country Status (10)

Country Link
US (2) US20080261243A1 (de)
EP (1) EP1797431B1 (de)
JP (1) JP4798801B2 (de)
CN (1) CN101036055B (de)
AT (1) ATE497165T1 (de)
CA (1) CA2582713A1 (de)
DE (1) DE602005026143D1 (de)
HK (1) HK1103439A1 (de)
MX (1) MX2007004079A (de)
WO (1) WO2006041959A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005034628B4 (de) * 2005-07-19 2007-08-23 Epigenomics Ag Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA
EP1803822A1 (de) * 2005-12-30 2007-07-04 Adnagen AG Verfahren zur individuellen Charakterisierung therapeutischer Zielmoleküle und seine Anwendung
US8557531B2 (en) * 2006-04-18 2013-10-15 Wellstat Biologics Corporation Detection of circulating endothelial cells
JP5025724B2 (ja) * 2006-04-18 2012-09-12 ウェルスタット バイオロジクス コーポレイション 循環腫瘍性細胞からのタンパク質の検出
EP2008107A4 (de) * 2006-04-18 2009-12-23 Wellstat Biologics Corp Detektion von steroidrezeptoren in zirkulierenden krebszellen und behandlung
US20080200342A1 (en) * 2007-02-15 2008-08-21 Rao Rupa S Device, Array, And Methods For Disease Detection And Analysis
JP2010525326A (ja) * 2007-04-19 2010-07-22 ウェルスタット バイオロジックス コーポレイション 分離されていない循環癌細胞由来のＨｅｒ−２／ｎｅｕタンパク質の上昇したレベルの検出および治療
KR100972618B1 (ko) * 2007-10-19 2010-07-27 국립암센터 허셉틴을 이용한 유방암 진단 키트, 조성물 및 이들을이용하여 허셉틴 민감성 ｈｅｒ２ 과발현 세포를 검출하는방법
JP5040597B2 (ja) * 2007-11-06 2012-10-03 日本電気株式会社 評価システム、評価方法および評価プログラム
EP2133433A1 (de) * 2008-06-09 2009-12-16 Centre Georges François Leclerc Verfahren zur Vorhersage der Reaktion auf eine Behandlung mit einem Antikörper gegen HER2
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
WO2010070117A1 (en) * 2008-12-18 2010-06-24 Universite Libre De Bruxelles Treatment method by the administration of anti-her2 targeted active compounds to patients with early breast cancer and her2-negative primary tumor
CN101880650B (zh) * 2009-05-04 2013-01-16 卢焕梅 一种从外周血中快速提取循环的非血缘性有核细胞的组合物和试剂盒及其应用
DK2591363T3 (en) * 2010-07-07 2017-12-11 Univ Michigan Regents DIAGNOSIS AND TREATMENT OF BREAST CANCER
FR2976294B1 (fr) 2011-06-10 2018-02-16 Universite De Nice Sophia Antipolis Methode de prediction de la reponse a un traitement avec un agent bloquant her2
CN102830228B (zh) * 2011-06-15 2015-01-21 格诺思博生物科技(上海)有限公司 定量分析循环肿瘤细胞的试剂及试剂盒
CN104122394A (zh) * 2013-04-23 2014-10-29 北京豪迈生物工程有限公司 人表皮生长因子受体2(Her-2)定量测定试剂盒及其检测方法
CN104561246B (zh) * 2013-10-18 2018-06-15 深圳先进技术研究院 血液中循环癌细胞的检测信号放大的方法与试剂盒
CN104568923A (zh) * 2014-12-01 2015-04-29 浙江省肿瘤医院 电化学发光检测外周血循环肿瘤细胞抗原的方法及试剂盒
CN104458710B (zh) * 2014-12-09 2017-11-14 山东省海盟生化科技有限公司 肿瘤早期高通量电化学发光检测方法的构建
CN106932583A (zh) * 2015-12-29 2017-07-07 北京大成生物工程有限公司 人表皮生长因子受体Her-2/neu定量检测试剂盒及其制备方法与应用
CN106226374B (zh) * 2016-08-18 2018-10-16 中南大学 一种人类表皮生长因子受体-2浓度的检测方法
CN106319069B (zh) * 2016-09-28 2020-02-14 河南乾坤科技有限公司 一种精确测定病源细胞的试剂盒及其应用
CN111257310B (zh) * 2020-03-10 2023-05-02 莆田学院附属医院（莆田市第二医院） 一种用于癌细胞识别的电致化学发光传感器的制备方法
CN117074692B (zh) * 2023-08-15 2024-04-09 复旦大学附属华山医院 一种关于脑脊液中肿瘤细胞her2抗原表达生物信息的识别方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451225B1 (en) * 1986-04-30 2002-09-17 Igen International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US6448091B1 (en) * 1988-11-03 2002-09-10 Igen International, Inc. Method and apparatus for improved luminescence assays using particle concentration chemiluminescence detection
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6884357B2 (en) * 1995-02-21 2005-04-26 Iqbal Waheed Siddiqi Apparatus and method for processing magnetic particles
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
ATE358276T1 (de) * 1995-06-07 2007-04-15 Bioveris Corp Elektrochemilumineszenz-enzymimmunoassay
US6117985A (en) * 1995-06-16 2000-09-12 Stemcell Technologies Inc. Antibody compositions for preparing enriched cell preparations
US6190870B1 (en) * 1995-08-28 2001-02-20 Amcell Corporation Efficient enrichment and detection of disseminated tumor cells
US6297062B1 (en) * 1996-03-07 2001-10-02 Bio-Magnetics Ltd. Separation by magnetic particles
US6890426B2 (en) * 1996-06-07 2005-05-10 Immunivest Corporation Magnetic separation apparatus and methods
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
DE69941689D1 (de) * 1998-02-12 2010-01-07 Univ Texas Verfahren und reagenzien zur raschen und effizienten isolierung zirkulierender krebszellen
AU2876900A (en) * 1999-02-10 2000-08-29 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids andmethods of use
US6300143B1 (en) * 1999-03-01 2001-10-09 Idec Pharmaceuticals Corporation Electrochemiluminescent assays for eukaryotic cells
US6969615B2 (en) * 1999-07-26 2005-11-29 20/20 Genesystems, Inc. Methods, devices, arrays and kits for detecting and analyzing biomolecules
AU1490801A (en) * 1999-11-15 2001-05-30 University Of Southern California Targeted delivery of therapeutic and diagnostic moieties
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
JP2005516217A (ja) * 2001-02-16 2005-06-02 イムニベスト・コーポレイション 循環している癌細胞の急速かつ効果的な単離のための方法および試薬
JP3313107B2 (ja) * 2001-03-22 2002-08-12 バイエル コーポレイション ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量
CA2462914A1 (en) * 2001-10-11 2003-04-17 Aviva Biosciences Corporation Methods, compositions, and automated systems for separating rare cells from fluid samples
MXPA05000403A (es) * 2002-07-15 2005-07-22 Genentech Inc Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2.
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
EP1816477A1 (de) * 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG Verwendung von natriuretischen Peptiden und Plazentawachstumsfaktorwerten zur Risikostratifizierung von für Herzstresstests ausgewählten Personen
EP2008107A4 (de) * 2006-04-18 2009-12-23 Wellstat Biologics Corp Detektion von steroidrezeptoren in zirkulierenden krebszellen und behandlung
US8557531B2 (en) * 2006-04-18 2013-10-15 Wellstat Biologics Corporation Detection of circulating endothelial cells
JP5025724B2 (ja) * 2006-04-18 2012-09-12 ウェルスタット バイオロジクス コーポレイション 循環腫瘍性細胞からのタンパク質の検出

Also Published As

Publication number Publication date
CA2582713A1 (en) 2006-04-20
JP4798801B2 (ja) 2011-10-19
WO2006041959A8 (en) 2008-01-31
WO2006041959A3 (en) 2006-06-15
CN101036055B (zh) 2011-06-29
EP1797431B1 (de) 2011-01-26
ATE497165T1 (de) 2011-02-15
MX2007004079A (es) 2007-06-15
US20080261243A1 (en) 2008-10-23
JP2008517253A (ja) 2008-05-22
EP1797431A4 (de) 2008-07-09
US20110070598A1 (en) 2011-03-24
EP1797431A2 (de) 2007-06-20
WO2006041959A2 (en) 2006-04-20
HK1103439A1 (en) 2007-12-21
CN101036055A (zh) 2007-09-12

Similar Documents

Publication Publication Date Title
DE602005026143D1 (de) Erkennung eines erhöhten spiegels von her-2/neu-proteinen in zirkulierenden krebszellen und dessen behandlung
Shelke et al. Importance of exosome depletion protocols to eliminate functional and RNA-containing extracellular vesicles from fetal bovine serum
MX2009011228A (es) Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.
BRPI0408315A (pt) anticorpo isolado, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos de produzir um anticorpo, de gerar um anticorpo ou fragmento de ligação de antìgeno, de regular uma resposta imune, de tratar ou prevenir um distúrbio associado com célula imune em um paciente, de tratar ou prevenir um distúrbio hiperproliferativo em um paciente, e, kit de diagnóstico
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
CA3011087A1 (en) Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor
EP3750916A3 (de) Monoklonale antikörper gegen das denguevirus-ns1-protein
NO20050775L (no) Fremgangsmater for identifisering av tumorer som responderer pa behandling med anti-ErbB2-antistoffer
EA201000245A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
DE59914997D1 (de) Krebszellen aus zellhaltigen körperflüssigkeiten, deren isolierung, verwendung sowie diese enthaltende mittel
NO20056236L (no) Behandling med anti-VEGF-antistoffer
BRPI0513135A (pt) bibliotecas de polinucleotìdeos, método de produção das mesmas, método de identificação de um polinucleotìdeo, região de ligação, meio adequado para uso em um, dispositivo eletrÈnico e dispositivo
Yang et al. A novel strategy for the discrimination of gelatinous Chinese medicines based on enzymatic digestion followed by nano-flow liquid chromatography in tandem with orbitrap mass spectrum detection
WO2005113831A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
Živković et al. Antigenotoxic properties of Agaricus blazei against hydrogen peroxide in human peripheral blood cells
Zhang et al. AAL exacerbates pro-inflammatory response in macrophages by regulating Mincle/Syk/Card9 signaling along with the Nlrp3 inflammasome assembly
WO2017100663A8 (en) Improved methods for treating her2-positive breast cancer
Mortensen et al. Quality of life in patients with multiple myeloma: a qualitative study
WO2019066617A3 (ko) 항 c-met 항체 및 이의 용도
WO2019066620A3 (ko) 항 c-met 항체 및 이의 용도
Lee et al. Effects of aging simulation program on nurses' attitudes and willingness toward elder care
Liu et al. New fungal protein from Pleurotus ferulae lanzi induces AMPK-mediated autophagy and G1-phase cell cycle arrest in A549 lung cancer cells
EP2192407A3 (de) Verfahren zum Nachweis von Zellimmunität und ihre Anwendung auf Arzneimittel
ATE181332T1 (de) Vom gtpase-aktivierenden protein (gap) abgeleitete peptide sowie deren diagnostische und therapeutische verwendung
Yang et al. Protective effect of soluble eggshell membrane protein hydrolysate on cardiac ischemia/reperfusion injury